50 results on '"Naik, Snehal"'
Search Results
2. Supplementary Data from Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant β-Catenin Activation in Colon Cancer
3. CCR Translation for the Article from Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant β-Catenin Activation in Colon Cancer
4. Phase I Trial, Quotient Code: QSC205947
5. Virtual Think-Tank on AAV vectors
6. P209 Etrasimod improves quality of life in adults with moderate-to-severe ulcerative colitis
7. S714 Etrasimod Improves Quality of Life in Adults With Moderate-to-Severe Ulcerative Colitis: Results From the Phase 2 OASIS Trial and Open-Label Extension
8. Challenges and Opportunities in IBD Clinical Trial Design
9. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
10. Imaging Cellular Networks and Protein-Protein Interactions In Vivo
11. Detection of Protein-Protein Interactions in Live Cells and Animals with Split Firefly Luciferase Protein Fragment Complementation
12. S0768 Early and Durable Symptom Control in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Etrasimod (APD334) in the Phase 2 OASIS Trial and Open Label Extension
13. Su1926 FECAL CALPROTECTIN AND C-REACTIVE PROTEIN LEVELS ARE CORRELATED WITH LONG TERM CLINICAL AND ENDOSCOPIC OUTCOMES: ANALYSIS OF THE OASIS OPEN LABEL EXTENSION TRIAL OF ETRASIMOD FOR ULCERATIVE COLITIS
14. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
15. Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
16. 764 Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study
17. 1006 – Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis
18. Tu1745 – Correlation of Fecal Calprotectin and C-Reactive Protein Concentrations with Clinical Outcomes and Endoscopic Disease Activity in Patients with Ulcerative Colitis Receiving Induction Therapy with Etrasimod
19. Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
20. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease
21. A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study: ACG Auxiliary Award (Member)
22. 233 - Low Infliximab Levels and Anti-Infliximab Antibodies Increase the Risk of Loss of Response to Infliximab in Pediatric IBD, a Prospective Pediatric Study
23. Mo1857 - Vedolizumab Levels During Induction are Associated with Long-Term Clinical and Endoscopic Remission in Patients with Inflammatory Bowel Disease
24. The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease
25. Vedolizumab Levels During Induction Are Associated With Remission in Patients With Inflammatory Bowel Diseases: 2017 Category Award (IBD): 2017 Presidential Poster Award
26. Long-Term Peritoneal Dialysis May Result in Vascular Changes Within the Peritoneal Cavity, Leading to Reduced Efficacy of Intravenous Antibiotics in Treatment of Bacterial Peritonitis
27. Torsion of a Wandering Spleen With Splenic and Gastric Varices Presenting as Abdominal Pain
28. Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) During Maintenance Therapy
29. Higher Vedolizumab Levels are Associated with Deep Remission in Patients with Crohn's Disease and Ulcerative Colitis on Maintenance Therapy with Vedolizumab
30. Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay
31. Association of Vedolizumab Concentrations Using Anser: Mobility Shift Assay and Clinical Response in IBD Patients in Clinical Practice
32. Testing Serum Infliximab and Serum Antibodies to Infliximab with a Drug Tolerant Assay Has a Significant Effect on Clinical Decision Making in the Treatment of Patients with Inflammatory Bowel Diseases
33. Analysis of Serum Adalimumab-Treated Patients Using the Anser ADA Homogenous Mobility Shift Assay
34. An Automated Agricultural Robot
35. The functional repertoire of rabbit antibodies and antibody discovery via next-generation sequencing
36. Pseudo-Static Stability Analysis of a Prototype Seawall
37. Establishment of paternal allele-specific DNA methylation at the imprinted mouseGtl2locus
38. Peroxisome Proliferator-Activated Receptor-α Activation Promotes Macrophage Reverse Cholesterol Transport Through a Liver X Receptor–Dependent Pathway
39. PPARγ activation redirects macrophage cholesterol from fecal excretion to adipose tissue uptake in mice via SR-BI
40. Dual-Color Click Beetle Luciferase Heteroprotein Fragment Complementation Assays
41. Alzheimer's disease target selection
42. P1-140: Common pathways and cellular processes as revealed by computational analysis of expression patterns from Tg4510 mice and human Alzheimer brains
43. Abstract LB-137: Reversibility of click beetle luciferase heteroprotein fragment complementation systems for imaging cancer pathways in live cells
44. Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant β-Catenin Activation in Colon Cancer
45. Both the Peroxisome Proliferator-Activated Receptor δ Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL-Derived Cholesterol
46. Real-time imaging of β-catenin dynamics in cells and living mice
47. Current State of Imaging Protein-Protein Interactions In Vivo with Genetically Encoded Reporters
48. Pharmacological Activation of Liver X Receptors Promotes Reverse Cholesterol Transport In Vivo
49. Regulation of Cysteinyl Leukotriene Type 1 Receptor Internalization and Signaling
50. Associations between intermediate filament protein and intermediate filament associated protein, and between intermediate filament associated protein and membrane protein, in wool
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.